234 related articles for article (PubMed ID: 25865021)
1. Did we IMPROVE-IT: thoughts on LDL targeting post-trial?
Packard C; Stezhka T
Expert Rev Cardiovasc Ther; 2015 May; 13(5):465-6. PubMed ID: 25865021
[TBL] [Abstract][Full Text] [Related]
2. [ACUTE CORONARY SYNDROME AND LIPID-LOWERING THERAPY. DOES THE IMPROVE-IT STUDY MAKE ANY DIFFERENCE?].
Lancellotti P; Pierard LA; Scheen AJ
Rev Med Liege; 2015 Sep; 70(9):450-5. PubMed ID: 26638446
[TBL] [Abstract][Full Text] [Related]
3. Effect of Low-Density Lipoprotein Cholesterol Lowering by Ezetimibe/Simvastatin on Outcome Incidence: Overview, Meta-Analyses, and Meta-Regression Analyses of Randomized Trials.
Thomopoulos C; Skalis G; Michalopoulou H; Tsioufis C; Makris T
Clin Cardiol; 2015 Dec; 38(12):763-9. PubMed ID: 26282344
[TBL] [Abstract][Full Text] [Related]
4. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population.
Blazing MA; Giugliano RP; Cannon CP; Musliner TA; Tershakovec AM; White JA; Reist C; McCagg A; Braunwald E; Califf RM
Am Heart J; 2014 Aug; 168(2):205-12.e1. PubMed ID: 25066560
[TBL] [Abstract][Full Text] [Related]
5. IMPROVE-IT: what have we learned?
Banach M; Nikolic D; Rizzo M; Toth PP
Curr Opin Cardiol; 2016 Jul; 31(4):426-33. PubMed ID: 27218683
[TBL] [Abstract][Full Text] [Related]
6. Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial.
Murphy SA; Cannon CP; Blazing MA; Giugliano RP; White JA; Lokhnygina Y; Reist C; Im K; Bohula EA; Isaza D; Lopez-Sendon J; Dellborg M; Kher U; Tershakovec AM; Braunwald E
J Am Coll Cardiol; 2016 Feb; 67(4):353-361. PubMed ID: 26821621
[TBL] [Abstract][Full Text] [Related]
7. Implications for Ezetimibe Therapy Use Based on IMPROVE-IT Criteria.
Virani SS; Akeroyd JM; Nambi V; Maddox TM; Gillette MA; Michael Ho P; Rumsfeld J; Petersen LA; Ballantyne CM
Am J Med; 2015 Nov; 128(11):1253-6. PubMed ID: 26071828
[TBL] [Abstract][Full Text] [Related]
8. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes.
Cannon CP; Giugliano RP; Blazing MA; Harrington RA; Peterson JL; Sisk CM; Strony J; Musliner TA; McCabe CH; Veltri E; Braunwald E; Califf RM;
Am Heart J; 2008 Nov; 156(5):826-32. PubMed ID: 19061694
[TBL] [Abstract][Full Text] [Related]
9. Comparison of effects of morning versus evening administration of ezetimibe/simvastatin on serum cholesterol in patients with primary hypercholesterolemia.
Yoon HS; Kim SH; Kim JK; Ko SH; Ko JE; Park SJ; Park MG; Lee JH; Hyon MS
Ann Pharmacother; 2011 Jul; 45(7-8):841-9. PubMed ID: 21693699
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW
Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
[TBL] [Abstract][Full Text] [Related]
11. Intensive LDL lowering therapy for prevention of recurrent cardiovascular events: a word of caution.
Simoons ML; Deckers JW
Eur Heart J; 2016 Feb; 37(6):520-3. PubMed ID: 26537621
[No Abstract] [Full Text] [Related]
12. The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.
Jimenez JG; Rosen JB; Pirags V; Massaad R; Hanson ME; Brudi P; Triscari J
Diabetes Obes Metab; 2013 Jun; 15(6):513-22. PubMed ID: 23279632
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety and LDL-C goal attainment of ezetimibe 10 mg-simvastatin 20 mg vs. placebo-simvastatin 20 mg in UK-based adults with coronary heart disease and hypercholesterolaemia.
Patel JV; Hughes EA
Int J Clin Pract; 2006 Aug; 60(8):914-21. PubMed ID: 16893434
[TBL] [Abstract][Full Text] [Related]
14. A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease.
Rosen JB; Jimenez JG; Pirags V; Vides H; Hanson ME; Massaad R; McPeters G; Brudi P; Triscari J
Diab Vasc Dis Res; 2013 May; 10(3):277-86. PubMed ID: 23288881
[TBL] [Abstract][Full Text] [Related]
15. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
McCormack T; Harvey P; Gaunt R; Allgar V; Chipperfield R; Robinson P;
Int J Clin Pract; 2010 Jul; 64(8):1052-61. PubMed ID: 20487050
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with ezetimibe/simvastatin versus statin monotherapy for low-density lipoprotein cholesterol reduction and goal attainment in a real-world clinical setting.
Friedman HS; Rajagopalan S; Barnes JP; Roseman H
Clin Ther; 2011 Feb; 33(2):212-24. PubMed ID: 21497705
[TBL] [Abstract][Full Text] [Related]
17. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
Daskalopoulou SS; Mikhailidis DP
Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
[TBL] [Abstract][Full Text] [Related]
18. On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT).
Blazing MA; Giugliano RP; de Lemos JA; Cannon CP; Tonkin A; Ballantyne CM; Lewis BS; Musliner TA; Tershakovec AM; Lokhnygina Y; White JA; Reist C; McCagg A; Braunwald E
Am Heart J; 2016 Dec; 182():89-96. PubMed ID: 27914504
[TBL] [Abstract][Full Text] [Related]
19. The safety of ezetimibe and simvastatin combination for the treatment of hypercholesterolemia.
Kei AA; Filippatos TD; Elisaf MS
Expert Opin Drug Saf; 2016; 15(4):559-69. PubMed ID: 26898906
[TBL] [Abstract][Full Text] [Related]
20. Ezetimibe: rescued by randomization (clinical and mendelian).
McPherson R; Hegele RA
Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):e13-5. PubMed ID: 25550209
[No Abstract] [Full Text] [Related]
[Next] [New Search]
